NAOV - NanoVibronix rockets 133% on UroShield device benefit in urinary tract infections

Nano cap NanoVibronix (NAOV) gallops 133% premarket on robust volume in reaction to positive results from an independent evaluation of its Uroshield device conducted in Britain showing sustained benefits in patients with urinary tract infections (UTIs).Patients using the device up to two years reported reduced UTIs, blockages, antibiotic usage, catheter changes and bladder maintenance solutions as well as fewer medical visits for emergency catheter changes.The company submitted the data to the advisory group NICE for consideration of routine access to UroShield via the National Health Service ((NHS)).

For further details see:

NanoVibronix rockets 133% on UroShield device benefit in urinary tract infections